Income Statement EXACT Therapeutics

Stocks

EXTX

NO0010852213

Biotechnology & Medical Research

Market Closed - Oslo Bors 18:45:00 01/09/2026 +04			5-day change	1st Jan Change
0.7500 ^NOK	-2.60%		0.00%	-45.65%

06-30	Exact Therapeutics to Delist from Euronext Growth Oslo in October	MT
06-26	EXACT Therapeutics AS Gets Positive Safety Review For 60 ?l/Kg Dose In Phase 2 ENACT Trial	RE

8136403794.yefgEdJVpyy2ow3yLxAzwWTUjq3u8FeFUu8ELrXbogA.ramxKYU2k2bs80a1Q0Rf8gie9_62pmTtN6BQeeP27XaK35Ak5hiWT-_5RA

Published financial data: EXACT THERAPEUTICS

Annual

Quarterly

Halfyear

YTD

LTM

Fiscal Period: December	2021 (NOK)	2022 (NOK)	2023 (NOK)	2024 (NOK)	2025 (NOK)
Revenues	-	-	-	-	-
Other Revenues, Total	52K	455K	4.46K	-	59K
Total Revenues	52K	455K	4.46K	-	59K
Gross Profit	52K	455K	4.46K	-	59K
Selling General & Admin Expenses, Total	18.52M	14.58M	22.55M	23.36M	28.98M
R&D Expenses	-	-	-	-	40.54M
Depreciation & Amortization - (IS)	1.82M	2M	2.09M	2.43M	3.68M
Other Operating Expenses	38.83M	24.64M	23.74M	27.06M	11.73M
Other Operating Expenses, Total	59.16M	41.23M	48.38M	52.85M	84.94M
Operating Income	-59.11M	-40.77M	-48.38M	-52.85M	-84.88M
Interest Expense, Total	-100K	-98.93K	-85.64K	-54.46K	-34.89K
Interest And Investment Income	340K	479K	945K	925K	2.62M
Net Interest Expenses	240K	380K	859K	870K	2.58M
Currency Exchange Gains (Loss)	6.95K	223K	-1.12M	-348K	-4.68M
Other Non Operating Income (Expenses)	274K	-396K	255K	329	10.88K
EBT, Excl. Unusual Items	-58.59M	-40.57M	-48.38M	-52.33M	-86.97M
Gain (Loss) On Sale Of Investments	-	-	-	-	-
EBT, Incl. Unusual Items	-58.59M	-40.57M	-48.38M	-52.33M	-86.97M
Income Tax Expense	-	-462K	-48.47K	-	-
Earnings From Continuing Operations	-58.59M	-40.1M	-48.33M	-52.33M	-86.97M
Net Income to Company	-58.59M	-40.1M	-48.33M	-52.33M	-86.97M
Net Income - (IS)	-58.59M	-40.1M	-48.33M	-52.33M	-86.97M
Net Income to Common Incl Extra Items	-58.59M	-40.1M	-48.33M	-52.33M	-86.97M
Net Income to Common Excl. Extra Items	-58.59M	-40.1M	-48.33M	-52.33M	-86.97M
Per Share Items
Net EPS - Basic	-1.95	-1.34	-1.51	-1.51	-1.37
Basic EPS - Continuing Operations	-1.95	-1.34	-1.51	-1.51	-1.37
Basic Weighted Average Shares Outstanding	29.98M	30M	32.08M	34.68M	63.26M
Net EPS - Diluted	-1.95	-1.34	-1.51	-1.51	-1.37
Diluted EPS - Continuing Operations	-1.95	-1.34	-1.51	-1.51	-1.37
Diluted Weighted Average Shares Outstanding	29.98M	30M	32.08M	34.68M	63.26M
Normalized Basic EPS	-1.22	-0.85	-0.94	-0.94	-0.86
Normalized Diluted EPS	-1.22	-0.85	-0.94	-0.94	-0.86
Supplemental Items
EBITDA	-57.66M	-39.3M	-46.75M	-51.08M	-81.81M
EBITA	-59.11M	-40.77M	-48.38M	-52.85M	-84.88M
EBIT	-59.11M	-40.77M	-48.38M	-52.85M	-84.88M
EBITDAR	-57.13M	-38.83M	-46.51M	-50.85M	-81.73M
Total Revenues (As Reported)	52K	455K	4.46K	-	59K
Effective Tax Rate - (Ratio)	-	1.14	0.1	-	-
Normalized Net Income	-36.62M	-25.35M	-30.24M	-32.71M	-54.35M
Interest on Long-Term Debt	103K	503K	86.44K	64.87K	31.68K
Supplemental Operating Expense Items
Research And Development Expense From Footnotes	34.49M	19.91M	19.74M	25.21M	40.54M
Net Rental Expense, Total	530K	465K	242K	232K	79.06K
Imputed Operating Lease Interest Expense	485K	217K	115K	110K	40.81K
Imputed Operating Lease Depreciation	45.31K	249K	127K	122K	38.25K
Stock-Based Comp., SG&A Exp. (Total)	4.16M	-398K	3.96M	2.82M	2.26M
Stock-Based Comp., Other (Total)	-	-	-	-	-
Total Stock-Based Compensation	4.16M	-398K	3.96M	2.82M	2.26M

Fiscal Period: December	2021 (NOK)	2022 (NOK)	2023 (NOK)	2024 (NOK)	2025 (NOK)
Assets
Cash And Equivalents	82.91M	69.39M	46.43M	99.54M	24.35M
Short Term Investments	20.78M	-	-	-	-
Total Cash And Short Term Investments	104M	69.39M	46.43M	99.54M	24.35M
Other Receivables	7.61M	8.14M	9.47M	6.69M	7M
Total Receivables	7.61M	8.14M	9.47M	6.69M	7M
Other Current Assets, Total	-	-	-	26.98M	29.16M
Total Current Assets	111M	77.53M	55.9M	133M	60.51M
Gross Property Plant And Equipment	9.67M	10.63M	13.68M	15.38M	21.07M
Accumulated Depreciation	-3.34M	-5.65M	-8.26M	-10.57M	-14.19M
Net Property Plant And Equipment	6.33M	4.97M	5.42M	4.81M	6.89M
Other Long-Term Assets, Total	-	1	1	15.19M	-
Total Assets	118M	82.51M	61.32M	153M	67.4M
Liabilities
Accounts Payable, Total	3.18M	9.55M	7.21M	11.66M	7.45M
Accrued Expenses, Total	6.33M	4.71M	6.17M	7.27M	9.59M
Current Portion of Leases	362K	496K	546K	594K	435K
Other Current Liabilities	656K	1.37M	1.56M	18.08M	19.22M
Total Current Liabilities	10.53M	16.13M	15.49M	37.6M	36.69M
Long-Term Leases	1.35M	1.19M	650K	52.39K	-
Other Non Current Liabilities	-	84.08K	82.1K	-	3
Total Liabilities	11.89M	17.4M	16.22M	37.65M	36.69M
Common Stock, Total	120K	120K	128K	253K	253K
Additional Paid In Capital	216M	93.52M	29.44M	96.64M	9.67M
Retained Earnings	-122M	-40.14M	-	-	-
Comprehensive Income and Other	12.01M	11.61M	15.53M	18.65M	20.78M
Total Common Equity	106M	65.11M	45.1M	116M	30.71M
Total Equity	106M	65.11M	45.1M	116M	30.71M
Total Liabilities And Equity	118M	82.51M	61.32M	153M	67.4M
Supplemental Items
ECS Total Shares Outstanding on Filing Date	29.99M	30M	32.08M	63.26M	63.26M
ECS Total Common Shares Outstanding	29.99M	30M	32.08M	63.26M	63.26M
Book Value / Share	3.53	2.17	1.41	1.83	0.49
Tangible Book Value	106M	65.11M	45.1M	116M	30.71M
Tangible Book Value Per Share	3.53	2.17	1.41	1.83	0.49
Total Debt	1.71M	1.69M	1.2M	647K	435K
Net Debt	-102M	-67.7M	-45.23M	-98.89M	-23.91M
Debt Equivalent Oper. Leases	4.24M	3.72M	1.93M	1.86M	632K
Account Code - Inventory Valuation	-	3	3	3	3
Machinery, Total	8.02M	8.22M	11.28M	12.96M	18.14M
Full Time Employees	7	10	12	12	11

Fiscal Period: December	2021 (NOK)	2022 (NOK)	2023 (NOK)	2024 (NOK)	2025 (NOK)
Net Income	-58.59M	-40.1M	-48.33M	-52.33M	-86.97M
Depreciation & Amortization - CF	1.83M	1.94M	2.09M	2.43M	3.68M
Depreciation & Amortization, Total	1.83M	1.94M	2.09M	2.43M	3.68M
(Gain) Loss on Sale of Investments - (CF)	-	-	-	-	-
Stock-Based Compensation (CF)	4.16M	-398K	3.96M	2.82M	2.26M
Other Operating Activities, Total	-521K	-208K	2.87K	-523K	2.09M
Change In Accounts Receivable	-1.62M	-534K	-1.32M	-39.39M	12.69M
Change In Accounts Payable	739K	5.46M	-690K	6.53M	-750K
Change in Other Net Operating Assets	-1.11M	-	-1.99K	-82.09K	-
Cash from Operations	-55.11M	-33.85M	-44.3M	-80.55M	-66.99M
Capital Expenditure	-1.63M	-251K	-3.09M	-1.51M	-5.32M
Cash Acquisitions	-	-	-	-	-
Investment in Marketable and Equity Securities, Total	-	20.37M	-	-	-
Other Investing Activities, Total	616K	479K	945K	925K	2.62M
Cash from Investing	-1.01M	20.6M	-2.15M	-581K	-2.7M
Long-Term Debt Repaid, Total	-438K	-507K	-581K	-598K	-761K
Total Debt Repaid	-438K	-507K	-581K	-598K	-761K
Issuance of Common Stock	508K	95.97K	25M	129M	-
Other Financing Activities, Total	-117K	-120K	-1.25M	5.47M	-34.89K
Cash from Financing	-47.39K	-531K	23.17M	134M	-795K
Foreign Exchange Rate Adjustments	-147K	261K	316K	-100K	-4.7M
Miscellaneous Cash Flow Adjustments	1	-1	-	-	-
Net Change in Cash	-56.31M	-13.52M	-22.96M	53.11M	-75.19M
Supplemental Items
Cash Interest Paid	100K	98.93K	85.64K	54.46K	34.89K
Levered Free Cash Flow	-34.63M	-19.34M	-29.35M	-31.46M	-55.69M
Unlevered Free Cash Flow	-34.57M	-19.27M	-29.29M	-31.43M	-55.67M
Change In Net Working Capital	1.99M	-4.92M	2.01M	2.14M	3.24M
Net Debt Issued / Repaid	-438K	-507K	-581K	-598K	-761K

Fiscal Period: December	2021 (NOK)	2022 (NOK)	2023 (NOK)	2024 (NOK)	2025 (NOK)
Profitability
Return on Assets	-25.67	-25.47	-42.05	-30.8	-48.1
Return on Total Capital	-27.66	-29.25	-53.47	-40.67	-72.01
Return On Equity %	-44.15	-46.95	-87.71	-65.17	-118.93
Return on Common Equity	-44.15	-46.95	-87.71	-65.17	-118.93
Margin Analysis
Gross Profit Margin %	100	100	100	-	100
SG&A Margin	35.62K	3.21K	506K	-	49.12K
EBITDA Margin %	-111K	-8.65K	-1.05M	-	-139K
EBITA Margin %	-114K	-8.97K	-1.09M	-	-144K
EBIT Margin %	-114K	-8.97K	-1.09M	-	-144K
Income From Continuing Operations Margin %	-113K	-8.82K	-1.08M	-	-147K
Net Income Margin %	-113K	-8.82K	-1.08M	-	-147K
Net Avail. For Common Margin %	-113K	-8.82K	-1.08M	-	-147K
Normalized Net Income Margin	-70.42K	-5.58K	-678K	-	-92.13K
Levered Free Cash Flow Margin	-66.6K	-4.25K	-658K	-	-94.39K
Unlevered Free Cash Flow Margin	-66.48K	-4.24K	-657K	-	-94.35K
Asset Turnover
Asset Turnover	0	0	0	-	0
Fixed Assets Turnover	0.01	0.08	0	-	0.01
Short Term Liquidity
Current Ratio	10.56	4.81	3.61	3.54	1.65
Quick Ratio	10.56	4.81	3.61	2.83	0.85
Operating Cash Flow to Current Liabilities	-5.23	-2.1	-2.86	-2.14	-1.83
Long Term Solvency
Total Debt/Equity	1.62	2.59	2.65	0.56	1.42
Total Debt / Total Capital	1.59	2.52	2.58	0.56	1.4
LT Debt/Equity	1.28	1.83	1.44	0.05	-
Long-Term Debt / Total Capital	1.26	1.78	1.4	0.04	-
Total Liabilities / Total Assets	10.11	21.09	26.45	24.58	54.44
EBIT / Interest Expense	-590.46	-412.17	-564.95	-970.59	-2.43K
EBITDA / Interest Expense	-572.18	-392.6	-540.52	-925.93	-2.33K
(EBITDA - Capex) / Interest Expense	-588.43	-395.14	-576.64	-953.57	-2.48K
Total Debt / EBITDA	-0.03	-0.04	-0.03	-0.01	-0.01
Net Debt / EBITDA	1.78	1.74	0.98	1.96	0.29
Total Debt / (EBITDA - Capex)	-0.03	-0.04	-0.02	-0.01	-0.01
Net Debt / (EBITDA - Capex)	1.73	1.73	0.92	1.9	0.28
Growth Over Prior Year
Total Revenues, 1 Yr. Growth %	-	774.07	-99.02	-	-
Gross Profit, 1 Yr. Growth %	-	774.07	-99.02	-	-
EBITDA, 1 Yr. Growth %	69.83	-31.85	18.98	9.26	60.15
EBITA, 1 Yr. Growth %	70.35	-31.02	18.65	9.25	60.59
EBIT, 1 Yr. Growth %	70.35	-31.02	18.65	9.25	60.59
Earnings From Cont. Operations, 1 Yr. Growth %	77.09	-31.55	20.52	8.27	66.18
Net Income, 1 Yr. Growth %	77.09	-31.55	20.52	8.27	66.18
Normalized Net Income, 1 Yr. Growth %	77.34	-30.76	19.27	8.16	66.18
Diluted EPS Before Extra, 1 Yr. Growth %	77.02	-31.43	12.69	-0	-8.96
Net Property, Plant and Equip., 1 Yr. Growth %	40.12	-21.43	8.96	-11.33	43.32
Total Assets, 1 Yr. Growth %	-30.9	-29.86	-25.68	149.84	-56.01
Tangible Book Value, 1 Yr. Growth %	-33.77	-38.43	-30.73	156.42	-73.42
Common Equity, 1 Yr. Growth %	-33.77	-38.43	-30.73	156.42	-73.42
Cash From Operations, 1 Yr. Growth %	112.04	-38.57	30.85	81.84	-16.83
Capital Expenditures, 1 Yr. Growth %	-58.96	-84.57	1.13K	-51.33	253.44
Levered Free Cash Flow, 1 Yr. Growth %	104.25	-44.17	51.76	7.21	77
Unlevered Free Cash Flow, 1 Yr. Growth %	104.06	-44.24	51.97	7.29	77.12
Compound Annual Growth Rate Over Two Years
Total Revenues, 2 Yr. CAGR %	-23.24	-	-70.72	-	263.79
Gross Profit, 2 Yr. CAGR %	-23.24	-	-70.72	-	263.79
EBITDA, 2 Yr. CAGR %	91.65	7.58	-9.96	14.01	32.28
EBITA, 2 Yr. CAGR %	92.31	8.4	-9.53	13.85	32.45
EBIT, 2 Yr. CAGR %	92.31	8.4	-9.53	13.85	32.45
Earnings From Cont. Operations, 2 Yr. CAGR %	98.8	10.1	-9.17	14.23	34.14
Net Income, 2 Yr. CAGR %	98.8	10.1	-9.17	14.23	34.14
Normalized Net Income, 2 Yr. CAGR %	97.67	10.81	-9.13	13.58	34.07
Diluted EPS Before Extra, 2 Yr. CAGR %	57.08	10.17	-12.1	6.15	-4.59
Net Property, Plant and Equip., 2 Yr. CAGR %	108.42	4.93	-7.47	-1.71	12.73
Total Assets, 2 Yr. CAGR %	50.25	-30.38	-27.8	36.26	4.84
Tangible Book Value, 2 Yr. CAGR %	58.23	-36.14	-34.69	33.22	-17.45
Common Equity, 2 Yr. CAGR %	58.23	-36.14	-34.69	33.22	-17.45
Cash From Operations, 2 Yr. CAGR %	110.27	14.13	-10.35	54.25	22.98
Capital Expenditures, 2 Yr. CAGR %	7.81	-74.84	37.9	144.9	31.16
Levered Free Cash Flow, 2 Yr. CAGR %	99.29	6.79	-7.95	27.56	37.76
Unlevered Free Cash Flow, 2 Yr. CAGR %	99.21	6.67	-7.95	27.69	37.85
Compound Annual Growth Rate Over Three Years
Total Revenues, 3 Yr. CAGR %	-78.96	72.7	-	-	-49.37
Gross Profit, 3 Yr. CAGR %	-78.96	72.7	-	-	-49.37
EBITDA, 3 Yr. CAGR %	97.38	35.78	11.25	-3.96	27.69
EBITA, 3 Yr. CAGR %	97.92	36.64	11.72	-3.66	27.68
EBIT, 3 Yr. CAGR %	97.92	36.64	11.72	-3.66	27.68
Earnings From Cont. Operations, 3 Yr. CAGR %	97.67	39.34	13.47	-3.7	29.44
Net Income, 3 Yr. CAGR %	97.67	39.34	13.47	-3.7	29.44
Normalized Net Income, 3 Yr. CAGR %	97.67	39.34	13.56	-3.7	28.94
Diluted EPS Before Extra, 3 Yr. CAGR %	57.09	19.16	11	-8.24	0.86
Net Property, Plant and Equip., 3 Yr. CAGR %	232.66	50.56	6.25	-8.78	11.46
Total Assets, 3 Yr. CAGR %	22.99	16.56	-28.85	9.21	-6.52
Tangible Book Value, 3 Yr. CAGR %	22.83	15.52	-34.39	3	-22.16
Common Equity, 3 Yr. CAGR %	22.83	15.52	-34.39	3	-22.16
Cash From Operations, 3 Yr. CAGR %	-	39.52	19.45	13.49	25.55
Capital Expenditures, 3 Yr. CAGR %	-	-43.6	-7.93	-2.55	176.75
Levered Free Cash Flow, 3 Yr. CAGR %	-	30.4	20.06	-3.15	42.28
Unlevered Free Cash Flow, 3 Yr. CAGR %	-	30.31	20.03	-3.12	42.41
Compound Annual Growth Rate Over Five Years
Total Revenues, 5 Yr. CAGR %	-	-43.45	-75.99	-	-
Gross Profit, 5 Yr. CAGR %	-	-43.45	-75.99	-	-
EBITDA, 5 Yr. CAGR %	-	52.21	44.2	26.61	19.23
EBITA, 5 Yr. CAGR %	-	52.44	44.71	27.02	19.59
EBIT, 5 Yr. CAGR %	-	52.44	44.71	27.02	19.59
Earnings From Cont. Operations, 5 Yr. CAGR %	-	52.18	44.83	28.69	21.32
Net Income, 5 Yr. CAGR %	-	52.18	44.83	28.69	21.32
Normalized Net Income, 5 Yr. CAGR %	-	52.53	44.86	28.4	21.36
Diluted EPS Before Extra, 5 Yr. CAGR %	-	-	24.53	13.78	4.48
Net Property, Plant and Equip., 5 Yr. CAGR %	-	75.65	99.39	26.95	8.8
Total Assets, 5 Yr. CAGR %	-	32.74	-0.61	24.07	-16.92
Tangible Book Value, 5 Yr. CAGR %	-	50.81	-4.6	22.3	-28.09
Common Equity, 5 Yr. CAGR %	-	50.81	-4.6	22.3	-28.09
Cash From Operations, 5 Yr. CAGR %	-	-	-	45.24	20.85
Capital Expenditures, 5 Yr. CAGR %	-	-	-	1.47	6.06
Levered Free Cash Flow, 5 Yr. CAGR %	-	-	-	29.26	26.85
Unlevered Free Cash Flow, 5 Yr. CAGR %	-	-	-	29.26	26.86